MA30042B1 - Composes calcilytiques - Google Patents
Composes calcilytiquesInfo
- Publication number
- MA30042B1 MA30042B1 MA31019A MA31019A MA30042B1 MA 30042 B1 MA30042 B1 MA 30042B1 MA 31019 A MA31019 A MA 31019A MA 31019 A MA31019 A MA 31019A MA 30042 B1 MA30042 B1 MA 30042B1
- Authority
- MA
- Morocco
- Prior art keywords
- calcilytic compounds
- compounds
- calcilytic
- synthesis
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
- C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des composés calcilytiques innovants, des compositions pharmaceutiques et leurs procédés de synthèse et d'utilisation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73873105P | 2005-11-22 | 2005-11-22 | |
US73906705P | 2005-11-22 | 2005-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30042B1 true MA30042B1 (fr) | 2008-12-01 |
Family
ID=38068035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31019A MA30042B1 (fr) | 2005-11-22 | 2008-06-11 | Composes calcilytiques |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090137557A1 (fr) |
EP (1) | EP1951244A4 (fr) |
JP (1) | JP2009516756A (fr) |
KR (1) | KR20080080136A (fr) |
AR (1) | AR057625A1 (fr) |
AU (1) | AU2006318275A1 (fr) |
BR (1) | BRPI0618900A2 (fr) |
CA (1) | CA2630117A1 (fr) |
EA (1) | EA200801414A1 (fr) |
IL (1) | IL191477A0 (fr) |
MA (1) | MA30042B1 (fr) |
TW (1) | TW200738649A (fr) |
UY (1) | UY29962A1 (fr) |
WO (1) | WO2007062370A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
CA2684633A1 (fr) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Derivees de pyrimidinone, et leurs methodes d'utilisation |
EP2224929B1 (fr) | 2007-12-17 | 2016-05-04 | Janssen Pharmaceutica, N.V. | Modulateurs imidazolo-, oxazolo- et thiazolopyrimidines de trpv1 |
WO2010039913A1 (fr) * | 2008-10-01 | 2010-04-08 | Glaxosmithkline Llc | Composé calcilytique |
WO2010039922A1 (fr) * | 2008-10-03 | 2010-04-08 | Glaxosmithkline Llc | Composés calcilytiques |
FR2937321B1 (fr) * | 2008-10-21 | 2010-10-22 | Rhodia Operations | Procede de fabrication de composes comprenant des fonctions nitriles |
US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
RU2701156C9 (ru) | 2012-07-18 | 2019-12-18 | Саншайн Лейк Фарма Ко., Лтд. | Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах |
GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
EP3251674A3 (fr) * | 2012-11-16 | 2018-02-21 | BioCryst Pharmaceuticals, Inc. | Nucléosides antiviraux contenant de l'azasucre |
JP6454348B2 (ja) | 2013-12-19 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 窒素複素環誘導体およびその医薬品への応用 |
US10183949B2 (en) | 2014-08-29 | 2019-01-22 | The University Of Tokyo | Pyrimidinone derivative having autotaxin-inhibitory activity |
CN118184502A (zh) * | 2024-05-16 | 2024-06-14 | 济南悟通生物科技有限公司 | 一种制备藜芦酮的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE424388T1 (de) * | 2001-12-06 | 2009-03-15 | Merck & Co Inc | Mitotische kinesinhemmer |
EP1558260A4 (fr) * | 2002-11-04 | 2006-10-25 | Nps Pharma Inc | Composes de quinazolinone utilises comme calcilytiques |
JP2006522159A (ja) * | 2003-04-07 | 2006-09-28 | エヌピーエス ファーマスーティカルズ インコーポレイテッド | カルシウム拮抗物質としてのピリミジノン化合物 |
AU2004311737A1 (en) * | 2003-12-19 | 2005-07-21 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
US7625912B2 (en) * | 2003-12-19 | 2009-12-01 | Merck & Co. Inc | Mitotic kinesin inhibitors |
JP2007536239A (ja) * | 2004-05-06 | 2007-12-13 | スミスクライン・ビーチャム・コーポレイション | カルシウム受容体アンタゴニスト化合物 |
WO2006066070A2 (fr) * | 2004-12-17 | 2006-06-22 | Nps Pharmaceuticals, Inc. | Constructions de promedicaments de composes de pyrimidinone utilises comme calcilytiques |
-
2006
- 2006-11-21 EA EA200801414A patent/EA200801414A1/xx unknown
- 2006-11-21 TW TW095143033A patent/TW200738649A/zh unknown
- 2006-11-21 CA CA002630117A patent/CA2630117A1/fr not_active Abandoned
- 2006-11-21 JP JP2008542512A patent/JP2009516756A/ja active Pending
- 2006-11-21 AU AU2006318275A patent/AU2006318275A1/en not_active Abandoned
- 2006-11-21 BR BRPI0618900-8A patent/BRPI0618900A2/pt not_active IP Right Cessation
- 2006-11-21 US US12/094,665 patent/US20090137557A1/en not_active Abandoned
- 2006-11-21 EP EP06839984A patent/EP1951244A4/fr not_active Withdrawn
- 2006-11-21 KR KR1020087014987A patent/KR20080080136A/ko not_active Application Discontinuation
- 2006-11-21 WO PCT/US2006/061150 patent/WO2007062370A2/fr active Application Filing
- 2006-11-22 UY UY29962A patent/UY29962A1/es not_active Application Discontinuation
- 2006-11-22 AR ARP060105122A patent/AR057625A1/es not_active Application Discontinuation
-
2008
- 2008-05-15 IL IL191477A patent/IL191477A0/en unknown
- 2008-06-11 MA MA31019A patent/MA30042B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
TW200738649A (en) | 2007-10-16 |
IL191477A0 (en) | 2009-02-11 |
JP2009516756A (ja) | 2009-04-23 |
EP1951244A2 (fr) | 2008-08-06 |
WO2007062370A3 (fr) | 2007-11-22 |
EP1951244A4 (fr) | 2010-08-25 |
AU2006318275A1 (en) | 2007-05-31 |
KR20080080136A (ko) | 2008-09-02 |
WO2007062370A2 (fr) | 2007-05-31 |
CA2630117A1 (fr) | 2007-05-31 |
EA200801414A1 (ru) | 2008-10-30 |
AR057625A1 (es) | 2007-12-05 |
BRPI0618900A2 (pt) | 2011-09-27 |
US20090137557A1 (en) | 2009-05-28 |
UY29962A1 (es) | 2007-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30042B1 (fr) | Composes calcilytiques | |
MA30497B1 (fr) | Anticorps et immunco-conjugues, et leurs utilisations. | |
MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
MA31502B1 (fr) | Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation | |
MA30531B1 (fr) | Anticorps anti-dll4 et leurs procedes d'utilisation | |
MA31433B1 (fr) | Inhibiteurs de la p70 s6 kinase | |
TW200621313A (en) | Pharmaceutical compositions | |
NO20071880L (no) | Diagnostic Compounds | |
MA29816B1 (fr) | Composes de benzimidazole thiophene | |
MA30910B1 (fr) | Anticorps et immunoconjugues, et leurs utilisations | |
IL185275A0 (en) | N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same | |
BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
MA31605B1 (fr) | Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation | |
MX2009005462A (es) | Analogos de 7,8-saturados-4,5-epoxi-morfinano. | |
HRP20080564T3 (en) | Dihydrotetrabenazines and pharmaceutical compositions containing them | |
CY1115919T1 (el) | Ενωσεις ενεργοποιησης τελομερασης και μεθοδοι χρησης αυτων | |
TW200716605A (en) | 2,6-quinolinyl derivatives, processes for preparing them and their uses | |
HRP20080529T3 (en) | Amide prodrug of gemcitabine, compositions and use thereof | |
NO20080991L (no) | Bazedoksifen acetat formuleringer | |
MA30331B1 (fr) | ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION | |
EA200701172A1 (ru) | 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение | |
TW200740781A (en) | Novel compounds | |
TNSN06012A1 (en) | Emulsifying systems containing azetidine derivatives | |
BRPI0408895A (pt) | formulações de cladribina para administração oral e transmucosal aperfeiçoada | |
NO20063293L (no) | Farmasoytiske forbindelser |